Alithea Genomics SA
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Alithea Genomics SA - overview
Established
2020
Location
Epalinges, -, Switzerland
Primary Industry
Biotechnology
About
Based in Epalinges, Switzerland, and founded in 2020 by Bart Deplancke, Daniel Alpern, and Riccardo Dainese, Alithea Genomics operates as a biopharma industry background in bioengineering, molecular biology, genomics, and lab operations and also provides transcriptomics solutions for research and biomarker discovery. As of September 2023, Riccardo Dainese is the Chief Executive Officer (CEO) of the company. In March 2026, Alithea Genomics SA raised CHF 3 million in seed funding led by Genku Ventures, with participation from Zurcher Kantonalbank and Novalis Biotech. Alithea Genomics SA is a business that has created a low-cost transcriptomics system to help in biomedical advances.
The company provides a transcriptomics platform that uses mercurius technology to reduce the costs of RNA sequencing while significantly boosting sample analysis capacity. This gives pharmaceutical companies the ability to do substantial biological research. The company plans to utilize the March 2026 funding to expand MERCURIUS™ DRUG-seq kit commercialization, develop new technologies, and grow transcriptomic data for AI and machine learning.
Current Investors
Novalis Biotech, TechU Ventures, Zurcher Kantonalbank
Primary Industry
Biotechnology
Sub Industries
Bioinformatics, Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy
Website
www.alitheagenomics.com
Company Stage
Angel & Seed
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.